Pepgen Inc. insider trading
Every open-market purchase and sale by Pepgen Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Pepgen Inc.’s insiders pay?
From February 13, 2024 to October 1, 2025, 5 insiders reported 6 open-market purchases and 0 sales not made under a pre-set plan in Pepgen Inc. Twelve months after each purchase was reported, the shares were −92.2% against the S&P 500 on average (median −92.2%), over 2 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 14, 2024 into $434 by November 2, 2026, −68.7% a year. It held shares 74% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,845 (+15.7% a year), and held throughout $15,670 (+18.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Mcarthur James G | President and CEO | 2 | — | — | 0 | — | April 22, 2025 |
| Kolchinsky Peter | Director | 1 | −113.9% (1) | 0% | 0 | — | February 13, 2024 |
| Oxford Science Enterprises PLC | Other | 1 | −70.6% (1) | 0% | 0 | — | October 1, 2025 |
| Ra Capital Healthcare Fund LP | Director | 1 | — | — | 0 | — | September 30, 2025 |
| Streck Paul | EVP, Head of R&D | 1 | — | — | 0 | — | June 2, 2025 |